These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8135468)

  • 1. A phase II multi-institutional study of estra-1,3,5(10)-triene-3,17 beta-diol, 3-benzoate, 17[[4-[4-[bis(2-chloroethyl)amino]phenyl]-1- oxobutoxy]acetate] (KM2210), a novel antitumor agent, for advanced and recurrent breast carcinoma.
    Kubota T; Abe O; Izuo M; Watanabe H; Enomoto K; Ohsawa N; Kuno K
    Anticancer Res; 1993; 13(6B):2361-5. PubMed ID: 8135468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mode of action of estra-1,3,5(10)-triene-3, 17 beta-diol, 3-benzoate, 17[4-[4-[bis(2-chloroethyl)amino]phenyl]-1-oxobutoxy] acetate] (KM2210) on MCF-7 human breast tumours transplanted into nude mice.
    Kubota T; Ishibiki K; Abe O; Kosano H; Ohsawa N; Hoffman RM
    Anticancer Res; 1993; 13(4):935-40. PubMed ID: 8352562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Enhancement of antitumor activity of mitomycin C against human breast carcinoma xenografts by pretreatment with KM 2210].
    Yamamoto T; Kubota T; Oka S; Josui K; Fujita S; Arisawa Y; Suto A; Inoue S; Kuzuoka M; Ishibiki K
    Gan To Kagaku Ryoho; 1990 Jan; 17(1):109-14. PubMed ID: 2105084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity and pharmacokinetics of estra-1,3,5 (10)-triene-3,17 beta-diol, 3-benzoate, 17-((4-(4-bis(2-chloroethyl)amino)phenyl)-1-oxobutoxy) acetate) (Bestrabucil) in human tumor xenografts serially transplanted into nude mice.
    Kubota T; Kawamura E; Suzuki T; Yamada T; Toyoda H; Miyagawa T; Kurokawa T
    Jpn J Clin Oncol; 1986 Dec; 16(4):357-64. PubMed ID: 3795532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic results in recurrent breast cancer with the use of Bestrabucil (KM2210)].
    Ueda T; Sakai K; Morimoto K; Nakatani S
    Gan To Kagaku Ryoho; 1987 Dec; 14(12):3285-9. PubMed ID: 3688892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Two cases of recurrent breast carcinoma achieving CR (complete response) with KM2210].
    Kubota T; Yamada Y; Kawamura E; Toyoda H; Miyagawa T; Kurokawa T
    Gan To Kagaku Ryoho; 1987 Aug; 14(8):2556-9. PubMed ID: 3619463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mode of action of estra-1,3,5(10)-triene-3,17 beta-diol 3-benzoate 17-[4-(4-bis(2-chloroethyl)amino)phenyl)-1-oxobutoxy)acet ate) on human breast carcinoma xenografts in nude mice.
    Kubota T; Koh J; Yamada Y; Oka S; Enomoto K; Ishibiki K; Abe O; Masui O; Asano K
    Jpn J Cancer Res; 1988 Nov; 79(11):1224-9. PubMed ID: 3147278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth-inhibitory action of an estrogen-chlorambucil conjugate (KM2210) in human breast cancer cell line MCF-7: its relation to reduction of estrogen receptor and transforming growth factor-alpha secretion.
    Kosano H; Kubota T; Ohsawa N; Yamamori S; Abe O; Inagaki H; Nagata N
    Cancer Res; 1992 Mar; 52(5):1187-91. PubMed ID: 1737378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes.
    Toi M; Saeki T; Aogi K; Sano M; Hatake K; Asaga T; Tokuda Y; Mitsuyama S; Kimura M; Kobayashi T; Tamura M; Tabei T; Shin E; Nishimura R; Ohno S; Takashima S
    Jpn J Clin Oncol; 2005 Jun; 35(6):310-5. PubMed ID: 15930037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
    Costanza ME; Berry D; Henderson IC; Ratain MJ; Wu K; Shapiro C; Duggan D; Kalra J; Berkowitz I; Lyss AP
    Clin Cancer Res; 1995 Jul; 1(7):699-704. PubMed ID: 9816035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
    Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
    Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Phase II study of NK 622 (toremifene citrate) in advanced breast cancer, a multicentral cooperative dose finding study].
    Tominaga T; Abe O; Izuo M; Nomura Y
    Gan To Kagaku Ryoho; 1993 Jan; 20(1):79-90. PubMed ID: 8422189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines.
    Pieńkowski T; Jagiello-Gruszfeld A
    Int J Clin Pharmacol Res; 2001; 21(3-4):111-7. PubMed ID: 12067140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.
    Fiorica J; Holloway R; Ndubisi B; Orr J; Grendys E; Boothby R; DeCesare S; LaPolla J; Hoffman M; Patel J
    Gynecol Oncol; 2002 Apr; 85(1):89-94. PubMed ID: 11925125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Oral high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer: a dose-response evaluation].
    Tominaga T; Izuo M; Nomura Y; Kubo K; Abe O; Enomoto K; Takatani O
    Gan To Kagaku Ryoho; 1982 Nov; 9(11):1994-2004. PubMed ID: 6223590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Phase II study of medroxyprogesterone acetate in advanced breast cancer].
    Ueno K; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Nakamura T; Ito Y; Imajo K; Ozeki H
    Gan To Kagaku Ryoho; 1986 Oct; 13(11):3198-202. PubMed ID: 2946264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
    Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
    Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.